Mathematics · Statistics and Probability
Subcutaneous Administration of Interleukin-2 and Interferon-alpha2b in Advanced Renal Cell Carcinoma: Long-Term Results
M.C. Locatelli, Giovanna Facendola, Giorgio Pizzocaro, Luigi Piva, Carlo Pegoraro, E. Bobbio Pallavicini, Signaroldi, Meregalli, Franco Lombardi, Giordano Beretta, F. Scanzi, Roberto Labianca
See on the mapAbstract
Clinical data have supported the combination of subcutaneous r-interleukin-2 (rIL-2) and r-interferon-alpha (rIFN-alpha) as a promising combination for advanced renal cell carcinoma (RCC), with a reduced toxicity. We evaluated the activity and safety of this outpatient immunotherapy and report on the clinical results and the long-term survival analysis. Objective responses was observed in 9 of 50 (18%) patients, 6 of whom (12%) achieved a complete response. Overall median survival is 12 months, six patients were surviving at a median follow-up of 24 months, and three (6%) are still progression-free.
More like this
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (
Aitchison, M., Bray, C. A., Van Poppel, H. +5 more